Are psychedelics riskier if you have bipolar disorder, a psychosis risk, or anxiety?
Yes for some conditions, and the risk is not the same for each one. Clinical research routinely screens out people with a personal or family history of psychotic disorders or bipolar disorder, and in a survey of 541 people with bipolar disorder who had used psilocybin, about one in three reported an unwanted effect, most often new or increasing manic symptoms. Anxiety is different: it is one of the most common short-lived effects during a session, and it is also a condition researchers are studying. None of this replaces a conversation with a licensed clinician who knows your history.
Most of the reassuring safety data on psychedelics comes from studies that left these conditions out on purpose. So the useful question is what is known for each condition, and what is not. Below is the published evidence on psychosis risk, bipolar disorder, and anxiety, with the limits of each study stated.
1. Why researchers screen for these conditions first
The 2008 Johns Hopkins safety guidelines for hallucinogen research, which later trials built on, exclude volunteers with a personal or family history of psychotic disorders or bipolar disorder (Johnson, Richards & Griffiths, 2008). The concern is that a psychedelic could trigger or worsen psychosis or mania in someone already vulnerable to it.
That screening has a consequence people often miss. When a trial reports few serious psychiatric events, it is describing people who passed that screen. It says little about people who would have been excluded. See who should not take psychedelics for the full exclusion list researchers use.
2. Psychosis and schizophrenia risk
Read that number carefully. It describes people whose hallucinogen use was serious enough to end in an emergency department, not everyone who has used a psychedelic. The authors say the findings do not establish that hallucinogens cause schizophrenia, that people with an underlying susceptibility may be the ones at higher risk, and that more information is needed on risk by type of hallucinogen and pattern of use. They also note that clinical trials exclude people with a personal or family history of schizophrenia and monitor participants closely, which is why they urge caution outside trial settings.
3. Bipolar disorder
The same respondents rated psilocybin about 4 out of 5 for helpfulness and about 1.6 out of 5 for harmfulness. Both findings are self-reported by people who chose to answer a survey, so they can't tell you how often harm happens. The lead researcher's own reading was that with roughly a third reporting adverse effects, "there is a need to be cautious."
Clinical evidence is thin. One open-label trial gave psilocybin with psychotherapy to 15 adults with treatment-resistant bipolar II depression; 11 (73%) met remission criteria at three weeks and 12 (80%) at twelve weeks, with no increase in mania, hypomania, or suicidality reported (Aaronson et al., JAMA Psychiatry, 2023, as summarized by HMP Global). There was no control group, the trial was funded by the drug's developer, participants were closely screened and monitored, and the hospital that ran it said the results can't be extrapolated to bipolar I disorder. It is an early signal for researchers, not evidence that psilocybin is safe for people with bipolar disorder.
4. Anxiety
Anxiety sits in a different place from psychosis and bipolar disorder. Several trials study people who have it. It is also one of the most common things to go wrong, briefly, during a session.
Those trials tracked mainly the first 48 hours, in screened participants, most of them without other health conditions. Outside trials, a survey of 613 U.S. adults who had used a classic psychedelic found that 59.1% had never had a challenging experience; 8.9% reported impairment lasting longer than a day, and 2.6% sought medical, psychiatric, or psychological help (Simonsson et al., 2023). A negative mindset, no preparation, and no psychological support were each associated with a harder time.
For what trials have found about psychedelics as a possible treatment for anxiety, see can psychedelics help with anxiety or PTSD? No psychedelic is FDA-approved for an anxiety disorder.
5. Medications matter as much as the diagnosis
In the same survey, lithium and other mood stabilizers were the only medication classes associated with more difficult experiences and higher odds of harm (Simonsson et al., 2023). Because those are the medications many people with bipolar disorder take, this is a second, separate reason for caution. More on interactions is on the page about psilocybin, SSRIs, and other antidepressants.
What the evidence does and doesn't cover
| Condition | What research shows | What is not known |
|---|---|---|
| Psychotic disorders, or a close family history of them | Excluded from research. People with hallucinogen-related emergency visits had a higher rate of later schizophrenia spectrum diagnoses. | Whether the substance causes the illness or reveals an existing vulnerability; risk by substance. |
| Bipolar disorder | Excluded from most research. About one in three surveyed users reported an unwanted effect, most often manic symptoms. One 15-person trial in bipolar II depression. | Almost everything about bipolar I; any controlled data; long-term outcomes. |
| Anxiety | Commonly studied. Short-lived anxiety during a session is about twice as likely with psilocybin as with a comparator. | How results in screened trial participants apply outside supervised settings. |
What a guide can and can't do here
A guide is not a clinician. A guide can't diagnose you, can't tell you whether your history makes a psychedelic experience too risky, and can't advise you on medication. In Oregon's licensed program, facilitators are barred from diagnosing and every client completes a preparation session covering intake, consent, and a safety and support plan before anything else (Oregon Health Authority).
What you can do is be completely honest about your history, including diagnoses in your family, and treat a guide who asks detailed screening questions, or who declines to work with you, as doing the job properly. If you have a diagnosis of bipolar disorder or a psychotic disorder, or a close relative with one, the first conversation belongs with a licensed mental-health clinician. If you are in crisis, call or text 988 (U.S.); in an emergency, call 911.
Talk your history through before anything else
Guides Collective connects you with vetted guides who discuss your health history and what to expect as part of the process, and every match starts with a free consultation, so the screening conversation happens before anything else.
Start the free 5-minute questionnaireFrequently asked questions
Can you take psychedelics if you have bipolar disorder?+
Can psychedelics cause psychosis or schizophrenia?+
Does a family history of schizophrenia or bipolar disorder matter?+
Do psychedelics make anxiety worse?+
Should I stop my medication before a psychedelic experience?+
Can a psychedelic guide tell me whether it is safe for me?+
Sources
- Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620.
- Myran DT, Pugliese M, Xiao J, et al. Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder. JAMA Psychiatry. 2025;82(2):142–150.
- Morton E, et al. Risks and benefits of psilocybin use in people with bipolar disorder: an international web-based survey. J Psychopharmacol. 2023.
- Vancouver Coastal Health Research Institute. Magic mushroom experiences among people with bipolar disorder (summary of Morton et al.). July 5, 2023.
- Aaronson ST, van der Vaart A, Miller T, et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized controlled trial. JAMA Psychiatry. Published online December 6, 2023.
- Valentino T. Use of psilocybin in bipolar II treatment clinical trial produces strong results (summary of Aaronson et al.). HMP Global Learning Network, December 12, 2023.
- Yerubandi A, Thomas JE, Bhuiya NMMA, et al. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(4):e245960.
- Simonsson O, Hendricks PS, Chambers R, et al. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. J Affect Disord. 2023 (study summary).
- Oregon Health Authority, Oregon Psilocybin Services. OPS Health and Safety fact sheet.
- Oregon Health Authority, Oregon Psilocybin Services. Facilitator Scope of Practice fact sheet.
Guides Collective is an informational platform that helps adults explore profiles of independent psychedelic guides. It is not a medical or mental-health provider and does not provide therapy, medical care, or psychedelic services.
All guides operate independently and are not employees, contractors, or agents of Guides Collective. Guides Collective does not verify guide-provided descriptions or credentials, does not recommend, endorse, or supervise any guide or service, and does not oversee or participate in any services guides offer.
Guides Collective does not provide or facilitate access to any substances. Each guide is solely responsible for their own services, communications, and compliance with local laws. Users are responsible for evaluating whether a guide's experience and approach are appropriate for their situation. No specific outcomes are promised or guaranteed.
Educational information on this page is provided for context only and does not constitute medical advice, diagnosis, or treatment. Research findings describe study populations under screened, supervised conditions and do not predict individual outcomes or apply to unsupervised use. If you are in crisis, call or text 988 (U.S.).